REFERENCES
1. Jiang Y, Jiang L, Li F, et al. The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol 2022;22:546.
2. Sripa B, Brindley PJ, Mulvenna J, et al. The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol 2012;28:395-407.
3. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-6.
4. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-11.
5. Cheng R, Du Q, Ye J, Wang B, Chen Y. Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma: a SEER database analysis. Medicine 2019;98:e18191.
6. Chan KM, Tsai CY, Yeh CN, et al. Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol 2018;18:180.
7. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014;60:1268-89.
8. Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings. Radiology 2011;260:148-57.
9. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008;28:747-69.
10. Granata V, Grassi R, Fusco R, et al. Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features. Radiol Med 2021;126:1584-600.
11. Granata V, Fusco R, Venanzio Setola S, et al. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol 2020;54:149-58.
12. Fattach HE, Dohan A, Guerrache Y, et al. Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging. Eur J Radiol 2015;84:1444-51.
13. Park HJ, Kim YK, Park MJ, Lee WJ. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 2013;38:793-801.
14. Zou X, Luo Y, Li Z, et al. Volumetric apparent diffusion coefficient histogram analysis in differentiating intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma. J Magn Reson Imaging 2019;49:975-83.
15. Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 2018;288:7-13.
16. Heye T, Merkle EM, Reiner CS, et al. Reproducibility of dynamic contrast-enhanced MR imaging. Part II. comparison of intra- and interobserver variability with manual region of interest placement versus semiautomatic lesion segmentation and histogram analysis. Radiology 2013;266:812-21.
17. Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 2022;12:28-51.
18. Kang Y, Lee JM, Kim SH, Han JK, Choi BI. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 2012;264:751-60.
19. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg 2014;149:432-8.
20. Spolverato G, Ejaz A, Kim Y, et al. Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg 2014;18:1284-91.
21. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014;149:565-74.
22. Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013;31:1188-95.
23. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93-9.
24. Ma K, Dong B, Wang L, et al. Nomograms for predicting overall survival and cancer-specific survival in patients with surgically resected intrahepatic cholangiocarcinoma. Cancer Manag Res 2019;11:6907-29.
25. Shen H, Zhang S, Xia Y, et al. A nomogram in predicting risks of intrahepatic cholangiocarcinoma after partial hepatectomy for hepatolithiasis. J Gastrointest Surg 2021;25:2258-67.
26. Aherne EA, Pak LM, Goldman DA, et al. Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics? Abdom Radiol 2018;43:2665-72.
27. Zhao L, Ma X, Liang M, et al. Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers. Cancer Imaging 2019;19:49.
28. Xue B, Wu S, Zhang M, et al. A radiomic-based model of different contrast-enhanced CT phase for differentiate intrahepatic cholangiocarcinoma from inflammatory mass with hepatolithiasis. Abdom Radiol 2021;46:3835-44.
29. Ren S, Li Q, Liu S, et al. Clinical value of machine learning-based ultrasomics in preoperative differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a multicenter study. Front Oncol 2021;11:749137.
30. Xue B, Wu S, Zheng M, et al. Development and validation of a radiomic-based model for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagologically diagnosed mass. Front Oncol 2020;10:598253.
31. Zhang J, Wu Z, Zhang X, et al. Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. ESMO Open 2020;5:e000910.
32. Wang Y, Shao J, Wang P, et al. Deep learning radiomics to predict regional lymph node staging for hilar cholangiocarcinoma. Front Oncol 2021;11:721460.
33. Xu L, Wan Y, Luo C, et al. Integrating intratumoral and peritumoral features to predict tumor recurrence in intrahepatic cholangiocarcinoma. Phys Med Biol 2021;66:125001.
34. Deng L, Chen B, Zhan C, et al. A novel clinical-radiomics model based on sarcopenia and radiomics for predicting the prognosis of intrahepatic cholangiocarcinoma after radical hepatectomy. Front Oncol 2021;11:744311.
35. Peng YT, Zhou CY, Lin P, et al. Preoperative ultrasound radiomics signatures for noninvasive evaluation of biological characteristics of intrahepatic cholangiocarcinoma. Acad Radiol 2020;27:785-97.
36. Liang W, Xu L, Yang P, et al. Novel nomogram for preoperative prediction of early recurrence in intrahepatic cholangiocarcinoma. Front Oncol 2018;8:360.
37. King MJ, Hectors S, Lee KM, et al. Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features. Cancer Imaging 2020;20:43.
38. Park HJ, Park B, Park SY, et al. Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. Eur Radiol 2021;31:8638-48.
39. Chu H, Liu Z, Liang W, et al. Radiomics using CT images for preoperative prediction of futile resection in intrahepatic cholangiocarcinoma. Eur Radiol 2021;31:2368-76.
40. Qin H, Hu X, Zhang J, et al. Machine-learning radiomics to predict early recurrence in perihilar cholangiocarcinoma after curative resection. Liver Int 2021;41:837-50.
41. Li MD, Lu XZ, Liu JF, et al. Preoperative survival prediction in intrahepatic cholangiocarcinoma using an ultrasound-based radiographic-radiomics signature. J Ultrasound Med 2022;41:1483-95.
42. Hao X, Liu B, Hu X, et al. A radiomics-based approach for predicting early recurrence in intrahepatic cholangiocarcinoma after surgical resection: a multicenter study. Annu Int Conf IEEE Eng Med Biol Soc 2021;2021:3659-62.
43. Yang Y, Zou X, Zhou W, et al. Multiparametric MRI-based radiomic signature for preoperative evaluation of overall survival in intrahepatic cholangiocarcinoma after partial hepatectomy. J Magn Reson Imaging 2022;56:739-51.
44. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:14-22.
45. Jiang W, Zeng ZC, Tang ZY, et al. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol 2011;22:1644-52.
46. Ma X, Liu L, Fang J, et al. MRI features predict microvascular invasion in intrahepatic cholangiocarcinoma. Cancer Imaging 2020;20:40.
47. Tsukamoto M, Yamashita YI, Imai K, et al. Predictors of cure of intrahepatic cholangiocarcinoma after hepatic resection. Anticancer Res 2017;37:6971-5.
48. Lee J, Kim SH, Kang TW, Song KD, Choi D, Jang KT. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology 2016;281:119-28.
49. Zhou Y, Wang X, Xu C, et al. Mass-forming intrahepatic cholangiocarcinoma: can diffusion-weighted imaging predict microvascular invasion? J Magn Reson Imaging 2019;50:315-24.
50. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-5.
51. Ali SM, Clark CJ, Mounajjed T, et al. Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience. HPB 2015;17:244-50.
52. Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015;41:120-7.
53. Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 2018;25:845-7.
54. Zhang XF, Lv Y, Weiss M, et al. Should utilization of lymphadenectomy vary according to morphologic subtype of intrahepatic cholangiocarcinoma? Ann Surg Oncol 2019;26:2242-50.
55. Tsilimigras DI, Sahara K, Paredes AZ, et al. Predicting lymph node metastasis in intrahepatic cholangiocarcinoma. J Gastrointest Surg 2021;25:1156-63.
56. Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB 2015;17:669-80.
57. Songthamwat M, Chamadol N, Khuntikeo N, et al. Evaluating a preoperative protocol that includes magnetic resonance imaging for lymph node metastasis in the cholangiocarcinoma screening and care program (CASCAP) in Thailand. World J Surg Oncol 2017;15:176.
58. Paño B, Sebastià C, Ripoll E, et al. Pathways of lymphatic spread in gynecologic malignancies. Radiographics 2015;35:916-45.
59. Park HS, Lee JM, Choi JY, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol 2008;190:396-405.
60. Hänninen EL, Pech M, Jonas S, et al. Magnetic resonance imaging including magnetic resonance cholangiopancreatography for tumor localization and therapy planning in malignant hilar obstructions. Acta Radiol 2005;46:462-70.
61. Park MS, Lee DK, Kim MJ, et al. Preoperative staging accuracy of multidetector row computed tomography for extrahepatic bile duct carcinoma. J Comput Assist Tomogr 2006;30:362-7.
62. Fábrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:67-78.
63. Zhou Y, Zhou G, Gao X, Xu C, Wang X, Xu P. Apparent diffusion coefficient value of mass-forming intrahepatic cholangiocarcinoma: a potential imaging biomarker for prediction of lymph node metastasis. Abdom Radiol 2020;45:3109-18.
64. Ji GW, Zhu FP, Zhang YD, et al. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol 2019;29:3725-35.
65. Meng ZW, Lin XQ, Zhu JH, Han SH, Chen YL. A nomogram to predict lymph node metastasis before resection in intrahepatic cholangiocarcinoma. J Surg Res 2018;226:56-63.
66. Annunziata S, Caldarella C, Pizzuto DA, et al. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. Biomed Res Int 2014;2014:247693.
67. Fowler KJ, Saad NE, Linehan D. Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer. Surg Oncol Clin N Am 2015;24:19-40.
68. Ma KW, Cheung TT, She WH, et al. Diagnostic and prognostic role of 18-FDG PET/CT in the management of resectable biliary tract cancer. World J Surg 2018;42:823-34.
69. Kirchner J, Sawicki LM, Deuschl C, et al. 18F-FDG PET/MR imaging in patients with suspected liver lesions: value of liver-specific contrast agent Gadobenate dimeglumine. PLoS One 2017;12:e0180349.
70. Dendl K, Koerber SA, Kratochwil C, et al. FAP and FAPI-PET/CT in malignant and non-malignant diseases: a perfect symbiosis? Cancers 2021;13:4946.
71. Hicks RJ, Roselt PJ, Kallur KG, Tothill RW, Mileshkin L. FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology? J Nucl Med 2021;62:296-302.
72. Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for staging pancreatic-, gastric- and cholangiocarcinoma: systematic review and head-to-head comparisons of diagnostic performances. Diagnostics 2022;12:1958.
73. Corona-Villalobos CP, Kamel IR. Functional volumetric MRI in assessing treatment response to intra-arterial therapy of primary and secondary liver tumors. J Comput Assist Tomogr 2014;38:513-7.
74. Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 2010;49:509-14.
75. Chung YE, Kim MJ, Park YN, et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009;29:683-700.
76. Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 2012;264:285-94.
77. Pandey A, Pandey P, Aliyari Ghasabeh M, et al. Unresectable intrahepatic cholangiocarcinoma: multiparametric mr imaging to predict patient survival. Radiology 2018;288:109-17.
78. Pandey A, Pandey P, Ghasabeh MA, et al. Baseline volumetric multiparametric mri: can it be used to predict survival in patients with unresectable intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization? Radiology 2018;289:843-53.
79. Cucchetti A, Cappelli A, Mosconi C, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int 2017;37:1056-64.
80. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using Yttrium-90 microspheres: results from a pilot study. Cancer 2008;113:2119-28.
81. Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440-8.
82. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013;24:1227-34.
83. Mosconi C, Cucchetti A, Bruno A, et al. Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. Eur Radiol 2020;30:4534-44.
84. Hermann AL, Dieudonné A, Ronot M, et al. SARAH trial group. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology 2020;296:673-84.
85. Roosen J, Westlund Gotby LEL, Arntz MJ, et al. Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery. Eur J Nucl Med Mol Imaging 2022;49:4705-15.
86. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321-30.
87. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 2016;27:1492-504.
88. Shields AF, Jacobs PM, Sznol M, et al. Immune modulation therapy and imaging: workshop report. J Nucl Med 2018;59:410-7.
89. Ku YJ, Kim HH, Cha JH, et al. Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. AJR Am J Roentgenol 2016;207:1146-51.
90. Ku YJ, Kim HH, Cha JH, et al. Predicting the level of tumor‐infiltrating lymphocytes in patients with triple-negative breast cancer: Usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 2018;47:760-6.
91. Zhang J, Wu Z, Zhao J, et al. Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. Eur Radiol 2021;31:3661-72.
92. Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol 2019;19:66-71.
93. Brunner TB, Blanck O, Lewitzki V, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019;132:42-7.
94. Brook OR, Thornton E, Mendiratta-Lala M, et al. CT imaging findings after stereotactic radiotherapy for liver tumors. Gastroenterol Res Pract 2015;2015:126245.
95. Navin PJ, Olson MC, Mendiratta-Lala M, Hallemeier CL, Torbenson MS, Venkatesh SK. Imaging features in the liver after stereotactic body radiation therapy. Radiographics 2022;42:2131-48.
96. Arimura H, Soufi M, Kamezawa H, Ninomiya K, Yamada M. Radiomics with artificial intelligence for precision medicine in radiation therapy. J Radiat Res 2019;60:150-7.
97. Peng Q, Shen Y, Fu K, et al. Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system. Aging 2021;13:7361-81.
